Iterum Therapeutics Q4 2025 Earnings Report

Iterum Therapeutics EPS Results

• Actual EPS: N/A
• Consensus EPS: -$0.20
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Iterum Therapeutics Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $0.51 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Iterum Therapeutics Announcement Details

• Quarter: Q4 2025
• Date: 4/3/2026
• Time: Before Market Opens
• Conference Call Date: N/A
• Conference Call Time: N/A

Iterum Therapeutics (NASDAQ:ITRM) is a clinical-stage biopharmaceutical company focused on the development and commercialization of anti-infective products targeting drug-resistant bacterial infections. The company’s research efforts are centered on novel therapeutic agents designed to address serious community-acquired and hospital-acquired infections where current treatment options are limited by emerging resistance.

The company’s lead product candidate, sulopenem, is being evaluated in both intravenous and oral formulations for the treatment of complicated urinary tract infections (cUTI) and intra-abdominal infections (IAI). Iterum’s development strategy seeks to leverage the broad spectrum of activity exhibited by sulopenem against resistant Gram-negative pathogens, with the goal of offering a seamless transition from hospital to outpatient care via its oral formulation.

Incorporated in 2014 and headquartered in Dublin, Ireland, Iterum Therapeutics maintains additional operations in the United States, including a presence in Malvern, Pennsylvania, to support clinical and regulatory activities. The company is backed by a management team and board with extensive experience in anti-infective drug discovery, clinical development and life-cycle management. Iterum continues to advance its pipeline through ongoing regulatory interactions and clinical studies aimed at meeting unmet medical needs in infectious diseases.